Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Purified Vero Rabies Vaccine · 1 trial · 1 indication
Rabies virus neutralizing antibody titer will be determined by the rapid fluorescent focus inhibition test (RFFIT)
| Arm | Type | Description |
|---|---|---|
| Purified Vero Rabies Vaccine Group | EXPERIMENTAL | Participants will receive the Purified Vero Rabies Vaccine (VRVg) |
| Imovax® Rabies Vaccine Group | EXPERIMENTAL | Participants will receive the Imovax® Rabies vaccine |
| Name | Type | Description |
|---|---|---|
| Purified Vero Rabies Vaccine (VRVg) | BIOLOGICAL | 0.5 mL, Intramuscular |
| Imovax® Rabies: inactivated rabies vaccine | BIOLOGICAL | 1.0 mL, Intramuscular |
Inclusion Criteria: * Aged 18 to \< 65 years on the day of inclusion * Informed consent form has been signed and dated - Able to attend all scheduled visits and comply with all trial procedures. Exclusion Criteria: * Subject is pregnant, or lactating, or of childbearing potential (to be considere...
Purified Vero Rabies Vaccine is an investigational vaccine being studied for rabies prevention. It is being evaluated in a simulated rabies post-exposure regimen, meaning it is tested for use after potential exposure to the rabies virus. The vaccine is currently in Phase 2 clinical development and is not yet approved.
Purified Vero Rabies Vaccine is being developed by Sanofi, a global biopharmaceutical company traded on the stock exchange under the ticker symbol SNY. Sanofi is conducting clinical trials to evaluate the vaccine's safety and immunogenicity in healthy volunteers.
Purified Vero Rabies Vaccine is currently in Phase 2 clinical development. It is an investigational vaccine, meaning it has not been approved by regulatory authorities. The vaccine is being studied in a completed Phase 2 trial that evaluated its use in a simulated rabies post-exposure regimen.
Purified Vero Rabies Vaccine has been studied in one clinical trial with the identifier NCT01877395. This Phase 2 trial, titled 'Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen,' was completed in the United States and enrolled 342 participants aged 18 years and older.
Purified Vero Rabies Vaccine is a vaccine, not a monoclonal antibody, despite the modality classification. It is designed to stimulate the immune system to produce antibodies against the rabies virus. The vaccine is being studied for use in a post-exposure regimen to prevent rabies after a potential exposure.